Featured
Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH
Chronic Diseases
Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH
Chronic Diseases
Chronic Diseases
Measuring Risk in R&D
R&D Insights
Measuring Risk in R&D
R&D Insights
R&D Insights
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Oncology, R&D Insights
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Oncology, R&D Insights
Oncology, R&D Insights
Screenshot 2025-10-30 154345.png
Oncology, R&D Insights
What indications should we focus on?
Oncology, R&D Insights
Oncology, R&D Insights
Suzetrigine drivers.jpg
Chronic Diseases
Journavx, a vast improvement over opioids in moderate acute pain
Chronic Diseases
Chronic Diseases
Enhertu regimen Figure (1).jpg
Oncology
Enhertu is poised to dominate first-line HER2+ breast cancer
Oncology
Oncology
Xolair-Figure JPG.jpg
Chronic Diseases
Xolair for food allergies: effective therapy at a high price
Chronic Diseases
Chronic Diseases
Leqembi-Figure.jpg
Chronic Diseases
Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price
Chronic Diseases
Chronic Diseases
Evrysdi-figure.jpg
Chronic Diseases
Evrysdi: A Potential Game-Changer for SMA Type 1 Patients
Chronic Diseases
Chronic Diseases
Cost Benefit Yescarta CAR T post.png
Oncology
CAR-T Outlook
Oncology
Oncology
Risperidone-vs.-Ulatorant.jpg
Chronic Diseases
Prospects for ulotaront in schizophrenia
Chronic Diseases
Chronic Diseases
Enhertu-vs.-Kadcyla.jpg
Oncology
Enhertu shows high clinical innovation in second-line metastatic breast cancer
Oncology
Oncology
 

Check Out Our Case Studies and Articles in Oncology and Chronic Disease Over the Years

Oncology

Chronic Disease

 
R&D Insights

R&D Insights